aTyr Pharma, Inc.
ATYR
$3.10
$0.082.65%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -17.42% | 5.97% | |||
| Gross Profit | 17.42% | -5.97% | |||
| SG&A Expenses | 7.67% | -0.18% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.80% | 4.78% | |||
| Operating Income | 12.80% | -4.78% | |||
| Income Before Tax | 13.28% | -5.86% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 13.28% | -5.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -50.00% | -- | |||
| Net Income | 13.28% | -5.84% | |||
| EBIT | 12.80% | -4.78% | |||
| EBITDA | 12.91% | -4.83% | |||
| EPS Basic | 20.55% | -0.93% | |||
| Normalized Basic EPS | 20.52% | -0.92% | |||
| EPS Diluted | 20.55% | -0.93% | |||
| Normalized Diluted EPS | 20.52% | -0.92% | |||
| Average Basic Shares Outstanding | 9.13% | 4.87% | |||
| Average Diluted Shares Outstanding | 9.13% | 4.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||